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EHR phenotypinga b s t r a c t
The rapidly increasing availability of electronic health records (EHRs) from multiple heterogeneous
sources has spearheaded the adoption of data-driven approaches for improved clinical research, decision
making, prognosis, and patient management. Unfortunately, EHR data do not always directly and reliably
map to medical concepts that clinical researchers need or use. Some recent studies have focused on
EHR-derived phenotyping, which aims at mapping the EHR data to speciﬁc medical concepts; however,
most of these approaches require labor intensive supervision from experienced clinical professionals.
Furthermore, existing approaches are often disease-centric and specialized to the idiosyncrasies of the
information technology and/or business practices of a single healthcare organization.
In this paper, we propose Limestone, a nonnegative tensor factorization method to derive phenotype
candidates with virtually no human supervision. Limestone represents the data source interactions
naturally using tensors (a generalization of matrices). In particular, we investigate the interaction of
diagnoses and medications among patients. The resulting tensor factors are reported as phenotype
candidates that automatically reveal patient clusters on speciﬁc diagnoses and medications. Using the
proposed method, multiple phenotypes can be identiﬁed simultaneously from data.
We demonstrate the capability of Limestone on a cohort of 31,815 patient records from the Geisinger
Health System. The dataset spans 7 years of longitudinal patient records and was initially constructed for
a heart failure onset prediction study. Our experiments demonstrate the robustness, stability, and the
conciseness of Limestone-derived phenotypes. Our results show that using only 40 phenotypes, we can
outperform the original 640 features (169 diagnosis categories and 471 medication types) to achieve
an area under the receiver operator characteristic curve (AUC) of 0.720 (95% CI 0.715 to 0.725). Moreover,
in consultation with a medical expert, we conﬁrmed 82% of the top 50 candidates automatically extracted
by Limestone are clinically meaningful.
 2014 Elsevier Inc. All rights reserved.1. Introduction
The rapidly increasing availability of electronic health records
(EHRs) from multiple heterogeneous sources has spearheaded the
adoption of data-driven approaches for improved clinical decision
making [1–4], prognosis [5–8], and patient management [9–12].
While knowledge discovery in EHRs show great promise towardsproviding better quality of care at lower costs [13–15], the vast
information captured pose difﬁculties for both medical practitio-
ners and data analysts [16]. EHR data offers many formidable chal-
lenges that has limited their utility for clinical research thus far.
These include diverse patient populations from providers who
may be using different, potentially incompatible EHR systems; het-
erogeneous information covering a variety of inter-related aspects
of patients such as diagnoses, medication orders, and laboratory
test ﬁndings [17,18]; sparsely sampled medical event sequences
with different time scales across patients [19–21]; and noisy,
Table 1
List of notations used in this paper.
Symbol Deﬁnition
A;B;K;P Matrix
ar The rth column in matrix A
X ;M Tensor
~i Tensor element index ði1; i2; . . . ; iNÞ
x~i Tensor element at index~i
XðnÞ Mode-n matricization of tensor X
 Element-wise multiplication
 Outer product
 Khatri-Rao product
A| Transpose of A
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ical research requires precise and concise medical concepts about
patients. The process of mapping raw EHR data into meaningful
medical concepts, or the task of learning the medically relevant
characteristics of the data [24,25] is referred to as EHR-based phe-
notyping. The phenotyping process can not only be used to identify
speciﬁc clinical characteristics important in the process of research
subject selection [26,27], but also improve the discovery process
such as optimizing interventions and predicting response to ther-
apy [24]. While the term EHR-based phenotyping has various
meanings [28], this paper focuses primarily on the process of
extracting medical concepts, or phenotypes.
Phenotypes encompass the entire spectrum of EHR data, using
both structured information (e.g. billing codes, laboratory reports,
and medication orders) and unstructured documents (e.g. clinical
notes, pathology and radiology reports) [27,29]. Signiﬁcant pro-
gress has been made in the generation and sharing of phenotypes
[29–33]. Examples of such large-scale phenotyping efforts are typ-
iﬁed by the Electronic Medical Records and Genomics (eMERGE)
Network [34] and the Observational Medical Outcomes Partner-
ship (OMOP) [35]. Furthermore, the eMERGE process supports
portability via a process that iteratively tests and reﬁnes the
phenotype at different institutions [29].
The development of EHR-derived phenotypes currently relies
primarily on rule-based, heuristic and iterative based approaches,
which take signiﬁcant time and expert knowledge to develop
[24,36,37]. Often, the phenotyping process requires a team effort
from clinicians, domain experts, and IT experts [24,37,38]. How-
ever, phenotypes are often disease-centric and the development
of a phenotype for a single disease can take months [39]. Further-
more, phenoytyping requires signiﬁcant interaction between the
domain experts and informaticians [37] and each team member
may bring his/her own biases, ignoring potentially useful informa-
tion [24]. Thus, high-throughput phenotyping, or efﬁcient and
automated phenotype extractions to reduce manual development,
has gained recent attention [24,36,37,26]. Data mining and
machine learning tools have been utilized to automate the pheno-
type generation process [24,36,37,26]. Yet, the current state of the
art high-throughput phenotyping cannot generate large amounts
of candidate phenotypes that simultaneously achieve good perfor-
mance without human annotated samples [37]. Thus, the limita-
tions of existing phenotyping efforts can be summarized as
follows:
 A requirement for human annotation of case and control sam-
ples, taking substantial time, effort, and expert knowledge to
develop.
 A lack of formalized methodology for deriving novel phenotypes
such as disease subtypes.
 A failure to incorporate an automated process to support porta-
bility across institutions.
To create a high-throughput phenotyping environment, the
phenotyping process needs to shift towards a more data-driven,
high-throughput approach, where multiple candidate phenotypes
are generated while minimizing human intervention [24]. Our
paper directly addresses all but the last limitation by focusing on
dimensionality reduction to automate the generation of
phenotypes.
One possible approach to automatically discover phenotypes
from EHR data is to use dimensionality reduction techniques
[24], which represent the original data using lower dimensional
latent space. Phenotyping takes high-dimensional EHR data and
maps it to medical concepts, where an ‘‘ideal’’ phenotype (i) is con-
cise and easily understood by a medical professional, (ii) repre-
sents complex interactions between several sources (e.g.diagnosis and medication), and (iii) maps to domain knowledge.
Each phenotype can be viewed as the deﬁnition of a particular
latent space along the multiple sources. Matrix factorization is a
common dimensionality reduction approach in high-dimensional
settings, but it may not concisely capture structured source inter-
actions, such as multiple medications prescribed to treat a single
disease. Thus, a more natural transformation is tensor factorization
which utilizes the multiway structure to produce concise and more
interpretable results.
This paper presents Limestone, a nonnegative tensor factoriza-
tion method to generate phenotype candidates without expert
supervision. Our algorithm is named after a sedimentary rock
obtained via geology mining, the extraction of valuable resources
from earth. Limestone (rock) has a wide diversity of uses and is
an excellent building stone. We view our nonnegative tensor
factorization model as a building block for high-throughput
phenotyping from EHR data. Our proposed model:
1. Achieves high-throughput phenotyping by deriving multiple
candidate phenotypes simultaneously from EHR data without
any user supervision or domain expertise.
2. Captures data source interaction, such as the diagnosis and
medication interaction from the same medical visit.
3. Generates concise and clinically meaningful phenotypes.
4. Produces stable phenotype deﬁnitions across multiple factor-
izations and small perturbations of the data.
We apply Limestone on real EHR data fromGeisinger Health Sys-
tem. The case-control dataset contains 31,815 patients. We use our
method to automatically derive multiple candidate phenotypes
from the dataset and analyze the factors for stability, conciseness,
predictive power, and clinical relevance. We also show that only
40 candidate phenotypes are needed as features to obtain better
predictive accuracy of patients at risk of heart failure than the ori-
ginal set of medical features (640), achieving an area under the
receiver operator characteristic curve (AUC) of 0.720 with a 95%
conﬁdence interval of (0.715, 0.725). Furthermore, 82% percent of
the ﬁrst 50 Limestone-derived phenotypes from the control popula-
tion are conﬁrmed by a medical expert to be clinically meaningful.
The remainder of the paper is structured as follows. Section 2
presents existing work on matrix factorization and summarizes
relevant existing tensor factorization approaches. Next, we detail
Limestone in Section 3. Section 4 demonstrates and evaluates our
proposed method on real EHR data. This is followed by a discussion
of the limitations and proposed future work in Section 5. Finally,
we summarize our work in the Section 6.2. Background and related work
Notation details. Table 1 provides a key to the symbols used in
this paper. We adopt the notation from [40] to maintain consis-
tency with the referenced tensor decomposition papers.
Fig. 1. EHR matrix representations and matrix factorization.
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Structured EHR data can be represented using a feature matrix.
The simplest representation for the data is a source independent
feature matrix, where each row denotes a patient and each column
represents a feature from a single source. Fig. 1a shows two matri-
ces from a diagnosis source and a medication source. For context,
in the Geisinger dataset, the diagnosis feature matrix contains
169 columns, where each column represents a single diagnosis
such as asthma. However, the source independent feature matrix
ignores potential interactions between the various sources, such
as medications prescribed to treat a speciﬁc diagnosis. To incorpo-
rate ‘‘same visit’’ interactions,1 a matrix whose column contains the
combinations between the sources can be used. Fig. 1b illustrates a
source interaction matrix for all diagnosis-medication combinations.
This matrix introduces two problems: (1) the data is sparse because
patients generally only experience a fraction of the diagnosis-medi-
cation combinations and (2) the data is high-dimensional (e.g.
149 471 possible combinations in the Geisinger case). Thus,
dimensionality reduction can assist both interpretability and scala-
bility of the data.
Matrix factorization (MF) is a common dimensionality reduc-
tion approach, which represents the original data using a lower
dimensional latent space. Standard MF approaches, which focus
primarily on numeric data, ﬁnd two lower dimensional matrices
such that when multiplied together approximately produce the
original matrix. The mathematical formulation is as follows, given
an N M matrix X, ﬁnd matrices W and H of size N  R and RM
such that:
X WH: ð1Þ
Fig. 1b illustrates the use of matrix factorization to derive phe-
notypes using the source interaction matrix. Although many
matrix decomposition techniques exist [41], principal component
analysis (PCA) and nonnegative matrix factorization (NMF) are
two common algorithms used to reduce the feature dimension.
PCA calculates a set of basis vectors, or principal components,
that minimizes the loss of information (i.e., the optimal approxi-
mation of the data in terms of least squared error). Generally, the
number of principal components (R) is much smaller than the
number of dimensions, which enables an encoding of the data as
linear combinations of the basis vectors. Thus, PCA transforms
the original, high-dimensional data to a lower-dimensional space
deﬁned by the principal components. One pitfall with PCA is
the loss of ‘‘interpretability’’ which stems from several issues:
(i) the principal components can have negative elements and
(ii) the observed data can be approximated using both positive1 Note that we do not explicitly deﬁne ‘‘same visit’’, as what constitutes a same visit
(e.g. a doctor visit, a hospital stay, etc) depends on the particular application.and negative combinations of the principal components. These
are problematic because, in certain domains, negative elements
and/or negative combinations are not easily interpretable [42,43].
For example, imagine the EHR feature matrix where each element
represents the number of times a diagnosis or medication is
recorded. Performing PCA on such a matrix results in a set of phe-
notypes, where each principal component deﬁnes the phenotype. A
positive value in the principal component indicates the presence of
a feature (diagnosis/medication) and a zero value denotes the
absence. However, a negative entry does not readily map to some
understanding about the feature’s relationship to the phenotype.
The desire to prevent negative components motivated NMF
[43]. Given a nonnegative matrix X, the NMF ﬁnds two nonnega-
tive matrices W and H that approximate X. Furthermore, the non-
negative constraint often leads to a sparse representation [43]. The
enhanced semantic interpretability of NMF has led to its use across
various ﬁelds such as mathematics, data mining, computer vision,
and chemometrics [44]. Applications of NMF to biomedical data
include discriminative feature selection from time–frequency rep-
resentation of EEG data [45], feature extraction from brain CT
images [46], and microarray gene data reduction for visualization
and clustering purposes [47].2.2. Tensor factorization
A tensor, or multiway array, is a generalization of a matrix (and
a vector and a scalar) to higher dimensions. A mode of a tensor
refers to a dimension, or way, of the tensor. The number of modes
in a tensor is also known as the order of the tensor. Tensor repre-
sentations are powerful because they can capture relationships
for high-dimensional data. An overview of tensors can be found
in [48–50].
A rank-one tensor can be written as the outer product of N vec-
tors, where the outer product is deﬁned as follows:
Deﬁnition 1. The outer product of N vectors, að1Þ  að2Þ      aðNÞ,
produces a Nth order tensor X where each element x~i
¼ xi1 ;i2 ;...;iN ¼ að1Þi1 a
ð2Þ
i2
   aðNÞiN .
Tensor factorization or decomposition is a natural extension of
matrix factorization and utilizes information from the multiway
structure that is lost when modes are collapsed to use matrix fac-
torization algorithms [48,49,51,52]. One of the common tensor
decompositions, CANDECOMP/PARAFAC (CP) [53,54], can be con-
sidered a higher-order generalization of singular value decomposi-
tion [48]. The CP model approximates the original tensor X as a
sum of R rank-one tensors:
X 
XR
r¼1
krað1Þr      aðNÞr ¼ sk;Að1Þ; . . . ;AðNÞt:
Phenotype R
Medication factor
Diagnosis factor
Patient
factor
Phenotype importance
Phenotype 1
Medication
Patient
Diagnosis
Fig. 2. Generating candidate phenotypes using CP tensor factorization.
2 The deﬁnition of the Khatri-Rao product is provided in the supplemental material.
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decomposition, where k is a vector of the weights kr and a
ðnÞ
r is the
rth column of AðnÞ. Fig. 2 conceptually illustrates the process of gen-
erating phenotypes via a CP decomposition. The details of our algo-
rithm to generate concise phenotypes are presented in Section 3.2.
While several other tensor decomposition methods exist (Kolda
and Bader provide a survey of existing models and example appli-
cations in their paper [48]), we focus on the CP decomposition for
two primary reasons: (i) it is a well-known and commonly applied
tensor factorization model [55], and (ii) the resulting structure
(R rank-one tensors) is well-suited for capturing medical concepts
in a concise and interpretable manner. The CP decomposition has
been used to complete missing data in medical questionnaires
[56], localize and extract artifacts from EEG data to analyze epilep-
tic seizures [57,58], and as an exploratory decomposition tool for
wavelet-transformed multi-channel EEG data [59].
Nonnegative tensor factorization (NTF) models have been pro-
posed for CP decompositions. Analogous to NMF, NTF requires
the elements of the factor matrices and the weights to be nonneg-
ative. Some examples of NTF models in the medical and bioinfor-
matics domain include the extraction of features from EEG data
[60,61] and gene-sample-time microarray data [62]. Cichocki
et al. provides a broad survey of practical and useful NMF and
NTF algorithms [42].
The standard CP model is well-suited for continuous data,
where the random variation follows a Gaussian distribution. How-
ever count data, which is nonnegative and discrete, is better
described using a Poisson distribution [63]. The nonnegative CP
alternating Poisson regression (CP-APR) model has been developed
to ﬁt count data [40]. We provide the CP-APR optimization prob-
lem formulation from [40] for convenience:
min f ðMÞ 	
X
~i
m~i 
 x~i logm~i|ﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄ{zﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄ}
Kullback-LeiblerðKLÞdivergence
subject toM ¼ sk;Að1Þ; . . . ;AðNÞt 2 X  sample space of M
X ¼ Xk X1     XN
Xk ¼ ½0;þ1ÞR  weights are nonnegative
Xn ¼ fA 2 ½0;1InRjjjarjj1 ¼ 18rg|ﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄ{zﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄ}
stochastic constraints on columns
;
ð2Þ
where~i represents the tensor element index ði1; i2; . . . ; iNÞ;X is the
observed tensor, andM is the CP tensor factorization that approx-
imates X .
The CP-APR algorithm solves the optimization problem via an
alternating minimization approach, where each subproblem com-
putes the solution for an individual mode while ﬁxing all the othermodes. CP-APR speciﬁes the mode-n matricization as X as
XðnÞ ¼ BðnÞPðnÞ [40], where
Let : BðnÞ ¼ AðnÞ
kPðnÞ ¼ ðAð1Þ  . . . Aðn
1Þ  Aðnþ1Þ  . . . AðNÞÞ|:
BðnÞ represents the weighed nth mode factor matrix and PðnÞ
denotes the ﬁxed part.2 The CP-APR optimization subproblem
(repeated from [40]) for the nth factor matrix is:
BðnÞ ¼ argmin
BP0
1|½BPðnÞ 
 XðnÞ  logðBPðnÞÞ1: ð3Þ
In Eq. (3), 1 corresponds to a vector of ones and captures the sum-
mation of the tensor elements shown in Eq. (2). The details of the
subproblem solver and the overall CP-APR algorithm can be found
in the paper [40].
NTF generally results in sparse representations. However, addi-
tional sparsity may be desired, for example, to improve factor
interpretability. Various techniques have been used to induce spar-
sity, such as extending an NMF sparseness measure [64], enforcing
L1 penalties on the factor matrices and/or the core matrix for
Tucker models [65–67], or regularizing the factors with both ‘1
and ‘2 norms [52].3. Limestone: phenotype tensor factorization
Limestone is a tensor factorization model to achieve high-
throughput phenotyping from EHR data. Our model extends the
CP-APR work to (i) produce concise phenotype deﬁnitions for bet-
ter interpretability and (ii) calculate a new patient’s phenotype
membership given the learned phenotypes. Fig. 3 illustrates the
conceptual diagram for the Limestone process. This section details
the tensor construction from raw EHR data, formally deﬁnes the
candidate phenotypes obtained via tensor factorization, and the
process to obtain the phenotype membership matrix for new
patients.
3.1. EHR tensor construction
The ﬁrst step in Limestone is to construct a count tensor from
the raw EHR data. In this paper, we focus on diagnoses and medi-
cations due to their prominence in existing phenotype deﬁnitions
[29,68]. However, our tensor construction can be generalized to
other EHR data. We use medication orders from the raw EHR data
that details the interaction between diagnoses and medications.
Each medication order contains the prescribed medication, the
Tensor 
Factorization
Projection
Phenotype 
Membership
New 
Patient
Fig. 3. A high-level depiction of the Limestone process by which candidate
phenotypes are generated and patients are projected onto the candidates.
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scription, and the date of the prescription.
Each patient is anchored using an index date (e.g. heart failure
diagnosis date). The observation window is deﬁned as a ﬁxed time
window of 2 years prior to the index date, as illustrated in Fig. 4.
Only data occurring during the observation window is used for
the raw EHR construction. The tensor is constructed using the
count of the co-occurrences between medications and diagnoses.
For Fig. 4, the patient has the following counts in the 2-year obser-
vation window encompassing 3 visits:
 2 counts of loop diuretics to treat coronary atherosclerosis;
 1 count of cardio-selective beta blockers to treat coronary
atherosclerosis;
 2 counts of sulfonylureas to treat diabetes;
 1 count of nitrates to treat coronary atherosclerosis; and
 1 count of ACE inhibitors to treat hypertension.
Note that the medication orders of sulfonylureas to treat diabe-
tes at time t0 and loop diuretics to treat congestive heart failure at
time t4 are outside the window and omitted from the tensor
construction.
The result is a third-order tensor with a patient mode, diagnosis
mode, and medication mode. Each tensor element denotes the
number of times medication m is prescribed to treat diagnosis d
for patient p. Slicing the tensor along the three different modes
yields the following views:
1. Patient mode: a matrix of the patient’s diagnoses and associated
medication treatment.Observation
Hypertension
ACE Inhibitors
Diabetes
Sulfonylureas
Coronary 
Atherosclerosis
Loop Diuretics
Coronary 
Atherosclerosis
Beta Blockers 
Cardio-selective
t0 t1 t2
Diabetes
Sulfonylureas
Diabetes
Sulfonylureas
Fig. 4. The observation window is deﬁned as a ﬁxed time window prior to the index date
The medication orders in gray are excluded during feature construction because they ar2. Diagnosis mode: a matrix of the prescribed medications to treat
the disease for all patients.
3. Medication mode: a matrix of all the patients and the diseases
treated with this medication.
The count tensor is a more natural representation of the inter-
actions between diagnoses and medications as it succinctly cap-
tures hierarchical information such as the set of medications that
are used to treat a disease. In addition, the Limestone implementa-
tion only stores the non-zero elements of the tensor for efﬁcient
memory storage.3.2. Phenotype deﬁnition via tensor factorization
Limestone extends the CP-APR model to derive phenotype can-
didates without supervision. The third-order count tensor is
approximated using the CP decompositionM ¼ sk;Að1Þ;Að2Þ;Að3Þt,
shown in Fig. 2. The factor matrix for the nth mode, AðnÞ, deﬁnes
the elements from the mode that comprise the candidate pheno-
types. Thus the jth candidate phenotype is deﬁned using the jth
column from the three factor matrices. Note that the stochasticity
constraint (i.e., the last line in Eq. 2) on the factor matrix yields a
conditional probability of the element’s membership to the pheno-
type. Given the jth phenotype, aðkÞij represents the probability of
seeing the ith element in the kth mode. Thus, the sum of the entries
for a mode element (
P
ja
ðkÞ
ij ) across all the phenotypes may not
equal 1. Furthermore, k allows us to automatically rank the candi-
date phenotypes in order of signiﬁcance, or the candidate pheno-
type’s ability to capture the tensor data. Fig. 2 illustrates the
tensor factorization of a patient by diagnosis by medication tensor
into R phenotypes.
We provide an illustrative example of a candidate phenotype
resulting from Limestone in Fig. 5. The percentage of patients with
the phenotype is calculated using the percentage of non-zero ele-
ments in the kth column of the patient factor matrix. The pheno-
type is deﬁned as patients diagnosed with hypertension and
taking three medications: (1) beta blockers cardio-selective, (2)
thiazides and thiazide-like diuretics, and (3) HMG CoA reductase
inhibitors. Limestone produced a single non-zero element along
the diagnosis factor and three non-zero components along the
medication factor.
Our proposed model incorporates a sparsity constraint to
minimize the presence of ‘‘minuscule and unnecessary’’ factor
components. We extend the original CP-APR model by employing
a hard-thresholding operator [69] to further reduce the phenotypeTime
Index Date
 Window = 2 years
Coronary 
Atherosclerosis
Nitrates
t3 t4
Congestive 
Heart Failure
Loop Diuretics
Coronary 
Atherosclerosis
Loop Diuretics
(e.g. diagnosis date) and is used to determine the data used for tensor construction.
e outside the observation window.
Fig. 5. An example of the kth candidate phenotype produced from the tensor
factorization, and the interpretation of the tensor factorization result. The green
text, blue, and red text correspond to non-zero elements in the patient, diagnosis,
and medication factors, respectively. (For interpretation of the references to colour
in this ﬁgure legend, the reader is referred to the web version of this article.)
Fig. 6. A new patient’s phenotype membership vector is computed by projecting
the new patient’s data onto the R candidate phenotypes in the purple dashed line.
(For interpretation of the references to colour in this ﬁgure legend, the reader is
referred to the web version of this article.)
3 http://www.sandia.gov/tgkolda/TensorToolbox/index-2.5.html.
4 https://code.google.com/p/pytensor/.
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minimizes KL divergence with a hard thresholding constraint,
replacing Eq. (2) with the following objective:
min
X
i
½mi 
 xi logmi|ﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄ{zﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄ}
CP-APR objective
þ c
X
j;n;r
1
aðnÞ
jr
>0
n o
|ﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄ{zﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄ}
hard-thresholding operator
; ð4Þ
where aðnÞjr denotes the jth component of the factor vector a
ðnÞ
r . Indi-
vidual components aðnÞjr that are below the threshold
ﬃﬃﬃﬃﬃ
2c
p
are set to
zero. Thus, the candidate phenotypes are concise, which should
offer better interpretability.
3.3. Projection on candidate phenotypes
Limestone also computes a new patient’s phenotype member-
ship vector by projecting their observed features onto the space
of existing candidate phenotypes. The phenotype membership vec-
tor ^ðaÞ1 is deﬁned as the convex combination of the candidate phe-
notypes, where the rth element of the vector, a^ð1Þr , is the probability
the patient belongs to rth phenotype. For example, a new patient’s
vector may indicate probabilities of 0.6, 0.3, and 0.1 for the pheno-
types of diabetes type 2, severe hypertension, and asthma, respec-
tively. Note that the phenotype membership vector is not
equivalent to the patient factor matrix, as the rth column of the
patient factor matrix Að1Þ represents a probabilistic interpretation
over the entire patient population for a single phenotype.
Our method uses the diagnosis factor matrix Að2Þ and the med-
ication factor matrix Að3Þ from the existing candidate phenotypes
to calculate the phenotype membership vector. Thus, given a
new patient’s data, cX , we wish to ﬁnd k^ and a^ð1Þ that best approx-
imates the new patient’s tensor:
cX X
r
k^r a^ð1Þr|ﬄ{zﬄ}
membership
 að2Þr  að3Þr
zﬄﬄﬄﬄﬄ}|ﬄﬄﬄﬄﬄ{phenotype definition
s:t
X
r
a^ð1Þr ¼ 1:
The projection onto the candidate phenotypes is illustrated in Fig. 6.
Therefore, the optimization for calculating the phenotype member-
ship vector is
b^ð1Þ ¼ argmin
bP0
1|½bPð1Þ 
 bXð1Þ  logðbPð1ÞÞ1
s:t
X
r
a^ð1Þr ¼ 1;
where b^ð1Þ ¼ ^ðaÞ1K^. The objective function of this problem is equiv-
alent to the optimization subproblem for mode 1. Therefore, we can
utilize the same iterative MM approach to solve for the optimal b^ð1Þ.The new patient’s phenotype membership vector a^ð1Þ is the entries
of b^ð1Þ normalized by the weights k^.
Software implementation.We developed a Python package based
on the Matlab Tensor Toolbox3 and Pytensor,4 a partial Python
implementation of the Matlab Tensor Toolbox. Our software package
implements the CP-APR algorithm described in [40] and provides the
functions to post-process the tensor decomposition to obtain concise
phenotypes and project new patients onto learned phenotypes.4. Heart failure case study
Our case study focuses on heart failure (HF), a leading cause of
healthcare use with a projected medical cost in 2015 of $32.5 bil-
lion [70]. Heart failure (HF) affects roughly 5.7 million people in
the US and is mentioned as the contributing cause for 1 out of
every 9 deaths [71]. Nearly a quarter of the patients hospitalized
with heart failure are readmitted within 30 days [72]. Thus far,
heart failure research has focused on epidemiology results, lifetime
risk assessments from the Framingham study [73,74], predictions
of hospital readmissions [75] or survival [76], and data-driven fea-
ture selection to complement known risk factors [77]. We demon-
strate Limestone on a dataset primarily used for heart failure onset
prediction studies and illustrate the potential of tensor factoriza-
tion to derive candidate phenotypes without the supervision of
domain experts. For this section, we will refer to candidate pheno-
types (discovered clusters) as phenotypes for simplicity.
Evaluation Metric Details. Our case study focuses on algorithmic
evaluation and qualitative analysis of Limestone-derived pheno-
types. We will evaluate the results in terms of similarity, concise-
ness, predictive power, and clinically meaningfulness. The metrics
we will use are the following:
1. Similarityðar ;brÞ ¼ ar|brkarkkbrk.
2. Conciseness = number of non-zero elements per mode.
3. Predictive power = area under receiver operator characteristic
curve (AUC) on a classiﬁcation task.
4. Clinical meaningfulness = domain expert’s opinion of whether
or not a Limestone-derived phenotype mapped to a medical
concept.
The similarity calculation is the cosine similarity between two
vectors, a component of the factor match score (FMS). FMS is
[40,78,79] commonly used to compare two tensor factorization
results, quantifying the closeness via a single number between
½0;1. However, FMS is an aggregate measure and can mask the
mode-speciﬁc similarity results. Therefore, we compare the cosine
along each mode, where the ideal value with two equivalent vec-
tors is 1. Phenotypes from the two tensor factorization results
are paired using an existing greedy FMS algorithm [40].
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The data for this study is based on real EHR data from the
Geisinger Health system, which contains over 7 years of longitudi-
nal patient records. The dataset has a diverse set of clinical infor-
mation that includes diagnoses comprised of ICD-9 billing codes
and medication records with generic drug names, pharmacy class
and subclass information. For this study, we analyze the following
sets of patients:
1. 4626 case patients, where each patient has at least 2 outpatient
HF diagnoses or 1 outpatient HF diagnoses with 2 or more HF
medications.
2. 27,189 group-matched control patients, where each case is
matched with 10 controls with the same gender, age, and clinic
information of the case patients.5 The control patients did not
meet the HF diagnosis criteria described above.
In the study, the heart failure index date for control patients is
the date of the matched case patient (e.g. if the case patient was
diagnosed on January 4, 2014, then the matched control patient
would use January 4, 2014 as the index date). Further details of
the cohort construction can be found in [23].
The Geisinger dataset recorded the interaction between diagno-
ses and medications in the medication orders table. Each medica-
tion order contains the prescribed medication, the diagnosis
(ICD-9 billing code) associated with the prescription, and the date
of the prescription. Any medication that was used to treat several
diagnoses has multiple entries corresponding to each diagnosis
code. The raw diagnosis code and medication captures information
at a fairly ﬁne-grained level, which is not ideal for analysis because
similar diagnoses and medications are considered independently.
To avoid this problem, we consolidated the individual diagnosis
codes and medications to higher level concepts using existing
medical hierarchies. Speciﬁcally, diagnosis codes are aggregated
using the Centers for Medicare and Medicaid (CMS) Hierarchical
Condition Categories (HCC) and medications deﬁned as pharmacy
subclass (e.g. ACE inhibitors, calcium channel blockers, etc.).6 This
resulted in 169 distinct HCC categories and 471 pharmacy subclass-
es. Therefore, the constructed tensor size for the control patients
population is 27;189 patients by 169 diseases by 471 medications,
where < 1% of the tensor are non-zero.
4.2. Algorithmic evaluation
The ﬁrst series of experiments focuses on evaluating the con-
vergence, stability, computation time, and sparsity of Limestone.
The following questions will be answered:
1. How many alternating minimization iterations are necessary to
converge to a stable solution?
2. Are the generated phenotypes stable towards perturbation and
different initializations?
3. How concise are the generated phenotypes?
4.2.1. Convergence
Given a ﬁxed number of phenotypes (R), we examine the KL
divergence (or the objective function values) as a function of the
number of alternating minimization iterations across 10 randomly
initialized factorizations of the case patients’ tensor. The KL5 Note that the same control patient may be matched by multiple cases. Thus, we
post-process the controls to make sure each control patient is only matched with one
case. The 19,071 duplicate controls are removed from the dataset.
6 Note that other hierarchies, such as the PheWAS code groups [80] could have
been employed.divergence is deﬁned as
P
~im~i 
 x~i logm~i. Fig. 7a shows the mean
and conﬁdence interval of the objective function values as the
number of iterations are increased. The ﬁrst 30 iterations result
in a signiﬁcant decrease in the negative log-likelihood. Above 80
iterations, there are only slight changes in the objective function
values with the values ﬂattening around 120 iterations. The results
suggest that less than 80 iterations are needed for convergence in
this dataset.4.2.2. Stability
Our algorithm uses randommatrices for the initial factor matri-
ces AðnÞ which can have an impact on the solution of the tensor fac-
torization. Thus, we study the effect of 10 random initializations of
Limestone, factorizing the case patients tensor with a ﬁxed number
of phenotypes and varying number of maximum iterations. Fig. 7b
illustrates the similarity score for each mode. The results show that
the similarity scores are high across all three modes beyond 70
iterations. In particular, the diagnosis and medication modes have
scores above 0.70. Note that the score of two random factors will
tend towards 0. As such, in this case study, we can conclude that
phenotype deﬁnitions are generally similar regardless of the initial
factor matrices.Iterations
Fig. 7. Objective function and similarity scores as a function of the number of total
iterations for the case patients tensor. The error bars indicate the 95% conﬁdence
interval.
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Fig. 9. The distribution of non-zero element values for 50 Limestone-derived
phenotypes.
206 J.C. Ho et al. / Journal of Biomedical Informatics 52 (2014) 199–211We also study the effect of noise, or perturbation, on the tensor
factorization results. Two experiments were performed:
1. Additive noise: Poisson noise (  Poissonð2Þ) is added to ran-
domly selected non-zero elements of original tensor, increasing
the overall mean of the tensor.
2. Additive and subtractive noise: Random addition or subtraction
of Poisson noise (  Poissonð2Þ) to randomly selected non-zero
elements of the original tensor. If subtraction results in a nega-
tive value, the value is set to zero and a random zero element of
the original tensor is selected for added noise to maintain the
overall mean and sparsity pattern of the original tensor.
The resulting ‘‘noised’’ tensor is then factorized and compared
to the original factorization using the similarity score.
Figs. 8a and b illustrates the average similarity scores for 10
random noisy tensors as a function of the percentage of noised ele-
ments. The results show a decay in the similarity score as the per-
centage of perturbed elements increases, where the effect is more
prominent in the additive and subtract noise results. However,
even when half of the non-zero elements are perturbed for both
experiments, the diagnosis and medication mode similarities
remain above 0.75, an impressive number given the high dimen-
sionality of our dataset. This observation suggests that phenotype
deﬁnitions are stable with regards to perturbation.0.5
0.6
0.7
0.8
0.9
1.0
0 10 20 30 40 50
Perturbation Percentage
Si
m
ila
rit
y
mode
Patient
Diagnosis
Medication
0.5
0.6
0.7
0.8
0.9
1.0
0 10 20 30 40 50
Perturbation Percentage
Si
m
ila
rit
y
mode
Patient
Diagnosis
Medication
Fig. 8. Similarity scores to the original tensor factorization results for perturbed
versions of the case patient tensor.4.3. Sparsity
Limestone uses a hard thresholding operator which enables a
tunable parameter to adjust the sparsity of the phenotypes. Fig. 9
shows a graph of the individual mode component values for the
diagnosis and medication modes for a case patients tensor factor-
ization. A majority of the nonzero elements in the diagnosis and
medication factor matrices are below 0.05 (the two points furthest
left in the plot). However, a reasonable number of the components
along the diagnosis factor have values above 0.75, while the med-
ication factors tend to have several medications (centered closer to
0.20). Thus, individual components less than a threshold of 0.05
contribute minimally to the phenotype deﬁnition in comparison
with the other non-zero elements and can be triaged to produce
concise phenotypes.
Fig. 10 shows the number of non-zero entries for the diagnosis
and medication factors using the suggested threshold from above.
Twelve of the phenotype were deﬁned using a single diagnosis. A
majority of the phenotype deﬁnitions contained less than ﬁve
medications. Thus, in this case study, Limestone produces concise
phenotypes at the threshold of 0.05, where all phenotypes contain
less than eight non-zero elements per factor.
4.4. Performance evaluation
The next series of experiments evaluate the Limestone-derived
phenotypes compared against the traditional dimensionality5
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Fig. 10. The number of non-zero entries per factor using a threshold of 0.05.
Fig. 11. The most signiﬁcant Limestone-derived phenotype and a ‘‘similar’’ NMF-derived phenotype with several matching diagnosis and medications. The Limestone
features are listed in descending order of the probabilistic values. The similar NMF features are listed ﬁrst, before listing the features in descending order based on element
value. The NMF threshold was adjusted to 0.001 to maintain similarities with the Limestone-derived phenotype.
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questions:
1. How do the Limestone-derived phenotypes compare to the phe-
notypes generated using nonnegative matrix factorization?
2. Do the phenotypes contain as much predictive power as tradi-
tional dimensionality reduction approaches?
4.4.1. NMF comparison
First, we compare the Limestone-derived phenotypes against
the traditional NMF approach.7 NMF is performed on the mode-1
matricization of the case patients tensor (Xð1Þ), a diagnosis-medica-
tion source interaction matrix.
Fig. 11 shows an example of the highest weighted (largest k)
Limestone-derived phenotype and the most similar NMF-derived
phenotype according to the cosine similarity score. For interpret-
ability purposes, only the non-zero diagnosis-medication combina-
tions with the largest weights are presented for the NMF-derived
phenotype. The phenotype deﬁnition is comprised of 1,549 diagno-
sis-medication combinations. The Limestone-derived phenotype is
concise and easier to interpret thanks to the structure of the deﬁ-
nition. The NMF-derived phenotype also illustrates the beneﬁt of
tensor factorization, in that as several medications are shared
across various diseases (e.g. sympathomimetics prescribed to treat
hypertension and vascular disease).
4.4.2. Predictive power
Limestone-derived phenotypes are evaluated on a classiﬁcation
task of predicting heart failure patients and compared against
three other feature sets. We use 10 random splits of the data,
where each split divides the patient population evenly (50% train
– 50% test) and maintains the same disease prevalence (otherwise
known as stratiﬁed sampling). The feature sets are then generated
for each split of the dataset:
1. Baseline: matrix with 640 columns (features), where 169 corre-
spond to the different diagnoses and the remainder represent
medications. This feature set ignores any potential interaction
between diagnoses and medications.7 PCA-derived phenotypes are not considered because negative elements lack a
clear clinical interpretation.2. PCA membership matrix: PCA is performed on the mode-1
matricization of the observed tensor (the source interaction
matrix 169 471 columns representing each diagnosis medica-
tion combination) with only the training population to obtain
the phenotype deﬁnitions, or H in Eq. (1). The PCA membership
matrix (W) is then computed for the entire population using the
phenotype deﬁnitions from the training population.
3. NMF membership matrix: Similar to the calculation for the PCA
membership matrix, with the exception that H and W are
nonnegative.
4. Limestone membership matrix: Limestone generates pheno-
types from the observed tensor (only patients in the training
set) and then projects all the patients onto the learned
phenotypes.
Note that for PCA, NMF, and Limestone, only the patient pheno-
type matrix (R columns) is used as the features to the predictive
model while the baseline uses all 640 columns. A ‘1 regularized
(Lasso) logistic regression predictive model is trained separately
on each of the four feature sets and the model’s predictive perfor-
mance is evaluated on the test set.8
Fig. 12 displays a plot of the area under the receiver operating
characteristic curve (AUC) while varying the number of pheno-
types in the data. All three methods have a signiﬁcant improve-
ment over the baseline. Moreover, the phenotyping methods
provide 20X feature reduction by only using 30 phenotyping fea-
tures to outperform the baseline using 640 features. Limestone
and NMF-derived phenotypes consistently achieve the highest pre-
dictive performance compared to PCA, especially above 30 pheno-
types. The results show that using only 40 phenotypes, we achieve
an AUC of 0.720 with a 95% conﬁdence interval of (0.715, 0.725).
Table 2a shows the mean and median number of non-zero ele-
ments per phenotype for PCA, NMF, and Limestone. For compari-
son purposes, Limestone phenotypes have been converted to the
diagnosis-medication representation (Að2Þ  Að3Þ). Thus, the results
for Limestone is equivalent to the number of non-zero diagnoses
elements multiplied by the number of non-zero medication com-
ponents. Limestone yields concise phenotypes compared to the
other two methods and provides a 94.7% reduction on the number
of non-zero elements in comparison to NMF.8 The ‘1 regularization term performs phenotype selection.
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random samples) for the three methods. PCA has the smallest
computation time because it has a closed form solution, while
our algorithm takes the longest. Thus, these results suggest that
Limestone can produce concise phenotypes while maintaining
similar computational complexity to NMF.Table 2
Average statistics from the 10 random splits using 50 phenotypes.
Type Mean Median
(a) Non-zero elements per phenotype
PCA 10917.50 10921.50
NMF 1533.62 1504.50
Limestone 34.79 32.00
Method Time (h)
(b) Computation time
PCA 0.001
NMF 1.648
Limestone 2.366
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0.68
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Fig. 12. Area under the receiver operating characteristic curve for the four feature
sets while varying the number of phenotypes. The error bars denote the 95%
conﬁdence interval and the dashed lines illustrated the conﬁdence interval using
the baseline feature set.
Table 3
Expert annotation of 50 Limestone-derived phenotypes from the case and control
tensors.
Tensor No Possible Yes
Case 14 14 22
Control 3 6 414.5. Domain expert evaluation
We now evaluate the clinical quality of the phenotypes. Our
experiment is meant to be a pilot study (a proof of concept) rather
than a formal survey designed to detect signiﬁcance. An experi-
enced cardiologist was provided with 50 candidate phenotypes
derived from the control patients and 50 candidate phenotypes
derived from the case patients. The phenotypes were ordered by
decreasing phenotype importance (k) and the diagnosis and medi-
cation factors were thresholded at 0.01.9 In addition, we presented
the expert with the percentage of patients that belonged to this phe-
notype. The percentage value was calculated by counting the num-
ber of patients in the patient factor that had a value greater than
1
10 and dividing by the total number of control patients. The med-
ical expert answered the following questions with a yes, no, or pos-
sible for each phenotype: ‘‘Are the combinations of diagnosis and
medications clinically meaningful?’’ We also asked the expert to
annotate each individual diagnosis and medication regarding its
meaningfulness to the phenotype and assign a short label for the
meaningful phenotypes.
Although the medical expert provided an overall analysis of
each phenotype, in several cases the response was different com-
pared to the individual annotations. Thus, the individual medica-
tion and diagnosis annotations were combined to produce an
overall score for the phenotype. We used a ‘‘lowest common
denominator’’ approach, such that if any element was tagged with
a ‘‘no’’ the phenotype would have an overall score of No. Generally,
if a phenotype contained a mixture of ‘‘possible’’ and ’’yes’’ annota-
tions, the phenotype was deemed possibly meaningful. The excep-
tion occurs when a single medication from the list is marked as
possibly meaningful while the remaining diagnoses and medica-
tions are marked as yes, the phenotype was tagged as a yes. Table
3 summarizes the aggregated answers for Limestone-derived phe-
notypes from both the control patients’ tensor and the case
patients’ tensor. A high percentage of the control phenotypes, 41
of the 50 (82%), were deemed clinically meaningful. Furthermore,
only 3 of the phenotypes were not clinically meaningful. The clin-
ical meaningfulness of the case patients derived phenotypes was
not as high as the control set, however only 14 of the 50 case phe-
notypes (28%) were not clinically meaningful.
We ﬁrst focus on the phenotypes derived from the control
patient tensor. The ﬁve most signiﬁcant (largest k) control pheno-
types are shown in Fig. 13. All but the second phenotype were
annotated as clinically meaningful (second was annotated as pos-
sibly meaningful) and the expert-assigned short label is displayed
in the ﬁgure. From the ﬁgure, four of the ﬁrst ﬁve Limestone-
derived phenotypes consist of a single diagnosis and a handful of
medications.
The experimental results also suggest the potential ability to
capture disease subtypes. Fig. 14 shows the meaningful pheno-
types relating to hypertension derived from the control patients
tensor. All three of the phenotypes share the same disease, but
have different combinations of medications which may indicate
disease severity. The domain expert assigned the following labels
for the three candidates: the fourth phenotype corresponds to9 Extra elements were included to present more information to the medical expert
at the cost of less concise phenotype deﬁnitions.patients with mild hypertension; the second phenotype is moder-
ate hypertension; and the sixth phenotype is the most severe of the
phenotypes.
For the six phenotypes labeled as possibly meaningful, four of
them contained the HCC category ‘‘major symptoms and abnor-
malities.’’ The ambiguous diagnosis made it difﬁcult for the medi-
cal expert to determine the exact medical concept. An example of
the comment for these four phenotypes is ‘‘Yes, but with a diagno-
sis of major symptoms, abnormality, it can mean anything.’’ The
broader class of control patients may have resulted in ambiguous
diagnoses for several of the phenotypes.
Only three of the control phenotypes were labeled as not clini-
cally meaningful. The predominant reason was the lack of a cohe-
sive diagnosis factor. One phenotype contained the single
diagnosis of ‘‘major symptoms and abnormalities’’, while the other
two had over ten unrelated diagnoses.
We next focus on the medical expert’s annotations of the phe-
notypes derived from the case patients tensor. Generally, the phe-
notypes labeled as clinically meaningful share the same medical
concepts as those in the clinically meaningful control patients
derived phenotypes. The differences in the tensor factorization
results occur for the phenotypes marked as possibly meaningful
or not clinically meaningful. For the fourteen phenotypes anno-
tated as possibly meaningful, the expert’s comment was ‘‘Looks
good except <insert a diagnosis> is meaningless.’’ Thus, 36 of
Fig. 13. The top ﬁve Limestone-derived phenotypes using the control patients’ tensor.
Fig. 14. Limestone-derived phenotypes from the control patients’ tensor relating to hypertension.
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to a clinical concept.
The remaining 14 case phenotypes were labeled as not clinically
meaningful. The medical expert’s comments for these phenotypes
were similar to the control phenotypes that lacked clinical
meaning. Phenotypes either had too many unrelated diagnoses or
uninformative diagnoses elements such as ‘‘history of disease’’,
‘‘minor symptoms, signs, ﬁndings’’, and ‘‘major symptoms and
abnormalities.’’5. Discussion
Our proposed method can identify multiple candidate pheno-
types concurrently from EHR data without any user supervision.
However, there remain several challenges towards its application
in a high-throughput setting. First, one of the most challenging
and unanswered tensor factorization questions relate to the choice
of rank (the number of phenotype candidates) [40]. A small number
of phenotypes may result in broad phenotype deﬁnitions while a
large number of phenotypes may result in ‘‘over-speciﬁcity’’ in the
phenotype deﬁnitions. Our heart failure case study used 50 as the
number of phenotypes to minimize the burden of the annotation
process while also illustrating the potential to achieve high-
throughput phenotyping. One possible option is to select the
number of phenotypes based on the performance of the candidate
phenotypes when used for subsequent predictive modeling tasks,
but discovering the best strategy will require further investigation.
The second challenge is that our clinical evaluation of Lime-
stone relied on a single medical expert to answer a question
regarding the clinical meaningfulness of the phenotypes. The clin-
ical evaluation was designed to be a proof of concept with theknowledge that a potential bias can inﬂuence our results. To dem-
onstrate statistical signiﬁcance, it will be necessary to design a
more extensive study that involves a panel of experts and asks var-
ious questions relating to the tensor derived phenotypes.
A third limitation of Limestone is that not all of the candidate
phenotypes were clinically meaningful. One potential explanation
is that the phenotypes labeled as possibly meaningful allude to
the potential of our method for knowledge discovery, generating
novel phenotypes that are currently unknown medical concepts.
Moreover, the higher number of clinically meaningful phenotypes
from the control population suggests that 50 phenotypes may not
be present in the case population. Further exploration of the results
in conjunction with a panel of experts are necessary to better
understand the differences between the case and control
populations.
Even though the candidate phenotypes generally mapped to a
medical concept, the medical expert’s annotations suggest the
need for incorporating user feedback to reﬁne phenotypes. Future
work can improve the Limestone process by using tensor factoriza-
tion to generate multiple candidate phenotypes from the observed
data and then present the phenotypes to domain experts. The med-
ical experts can then approve, reject, or alter the phenotypes such
that all phenotypes are clinically meaningful. Although the pheno-
type generation process requires some human intervention, the
goal would then be to minimize the interaction time necessary
to produce meaningful phenotypes. Furthermore, existing pheno-
types can be utilized to avoid repeated derivation of the same
deﬁnitions.
Fourth, the clinical evaluation results suggest the potential abil-
ity to generate phenotypes that capture disease subtypes under an
unsupervised setting. For instance, the three candidate phenotypes
shown in Fig. 14 captured differing disease severities in the control
210 J.C. Ho et al. / Journal of Biomedical Informatics 52 (2014) 199–211population. Nonetheless, further analysis is necessary to determine
whether the candidate phenotypes reﬂect the true patient status.
Moreover, future work should analyze the efﬁciency of Limestone
to capture disease subtypes both in this dataset and other EHR
datasets.
Fifth, although our paper only focused on the tensor con-
structed with diagnoses and medications, the EHR tensor can be
constructed using various other structured data sources. Prelimin-
ary experiments using several other data sources (though outside
the scope of this speciﬁc study) such as laboratory tests, imaging
results, and patient symptoms yielded similar results in terms of
conciseness and predictive power. For unstructured sources, such
as clinical notes, Limestone will require an additional preprocess-
ing step (e.g. text mining or natural language processing). How-
ever, our current methodology only supports a single tensor. EHR
data is comprised of multiple sources which may not naturally ﬁt
into a single tensor representation. Therefore, Limestone will need
to be extended to factorize multiple tensors to fully utilize all EHR
data.
Finally, our proposed method does not address portability
across institutions. Candidate phenotypes generated at one site
may be somewhat different from candidate phenotypes generated
at another site. Thus, Limestone-derived phenotypes may not be
readily transportable and executed at various other institutions.
Future work should focus on the portability of Limestone-derived
phenotypes while allowing variations in the phenotype deﬁnition.
6. Conclusion
This paper introduced Limestone, a nonnegative tensor factor-
ization method to generate phenotypes without supervision. Lime-
stone can generate numerous phenotypes simultaneously from
data with minimal human intervention. The resulting tensor fac-
tors serve as phenotype candidates that automatically reveal
patient clusters on speciﬁc diagnoses and medications. Moreover,
our method can derive concise phenotype deﬁnitions, potentially
capture disease subtypes that may not otherwise be easily deﬁned,
and produce consistent phenotype deﬁnitions for multiple factor-
izations of the same data.
Our results on 31,815 patient records from Geisinger Health
System demonstrate the stability, conciseness, predictive power,
and clinical meaningfulness of Limestone-derived phenotypes.
They underscore the promise of Limestone for high-throughput
phenotyping that generally results in meaningful phenotypes.
Future work will focus on incorporating domain expertise in the
phenotype generation process and extending the methodology to
factorize multiple tensors simultaneously.
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